Veeva Systems Inc. $VEEV Shares Sold by Vontobel Holding Ltd.

Vontobel Holding Ltd. lessened its holdings in Veeva Systems Inc. (NYSE:VEEV) by 26.7% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 8,514 shares of the technology company’s stock after selling 3,104 shares during the period. Vontobel Holding Ltd.’s holdings in Veeva Systems were worth $2,536,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in VEEV. Sigma Planning Corp raised its holdings in Veeva Systems by 1.2% in the second quarter. Sigma Planning Corp now owns 3,328 shares of the technology company’s stock valued at $958,000 after acquiring an additional 39 shares in the last quarter. Keybank National Association OH increased its position in shares of Veeva Systems by 1.4% in the 2nd quarter. Keybank National Association OH now owns 3,088 shares of the technology company’s stock valued at $889,000 after purchasing an additional 42 shares during the last quarter. Facet Wealth Inc. raised its holdings in shares of Veeva Systems by 3.3% in the 2nd quarter. Facet Wealth Inc. now owns 1,342 shares of the technology company’s stock valued at $381,000 after purchasing an additional 43 shares in the last quarter. Triangle Securities Wealth Management raised its holdings in shares of Veeva Systems by 0.8% in the 2nd quarter. Triangle Securities Wealth Management now owns 5,782 shares of the technology company’s stock valued at $1,665,000 after purchasing an additional 45 shares in the last quarter. Finally, Emerald Advisers LLC lifted its position in shares of Veeva Systems by 1.8% during the 2nd quarter. Emerald Advisers LLC now owns 2,679 shares of the technology company’s stock worth $771,000 after purchasing an additional 47 shares during the last quarter. Hedge funds and other institutional investors own 88.20% of the company’s stock.

Insider Activity at Veeva Systems

In related news, insider Thomas D. Schwenger sold 3,350 shares of the stock in a transaction on Thursday, October 2nd. The shares were sold at an average price of $300.04, for a total transaction of $1,005,134.00. Following the completion of the sale, the insider owned 23,773 shares in the company, valued at $7,132,850.92. This represents a 12.35% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Eleni Nitsa Zuppas sold 6,000 shares of the firm’s stock in a transaction on Tuesday, October 7th. The stock was sold at an average price of $306.62, for a total transaction of $1,839,720.00. Following the transaction, the insider directly owned 25,325 shares in the company, valued at $7,765,151.50. The trade was a 19.15% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 24,665 shares of company stock worth $7,438,000 in the last 90 days. 10.30% of the stock is owned by insiders.

Veeva Systems Stock Up 0.5%

Shares of NYSE VEEV opened at $224.36 on Friday. The business has a 50-day moving average price of $259.07 and a 200 day moving average price of $274.78. The stock has a market cap of $36.88 billion, a PE ratio of 43.65, a price-to-earnings-growth ratio of 1.65 and a beta of 1.05. Veeva Systems Inc. has a 52-week low of $201.54 and a 52-week high of $310.50.

Veeva Systems (NYSE:VEEV) last released its quarterly earnings results on Thursday, November 20th. The technology company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.95 by $0.09. The company had revenue of $0.81 million for the quarter, compared to analyst estimates of $792.37 million. Veeva Systems had a return on equity of 13.68% and a net margin of 27.93%.The firm’s revenue was up 16.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.75 earnings per share. Veeva Systems has set its FY 2026 guidance at 7.930-7.93 EPS and its Q4 2026 guidance at 1.920-1.920 EPS. Sell-side analysts anticipate that Veeva Systems Inc. will post 4.35 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts recently commented on the company. Needham & Company LLC reissued a “buy” rating and issued a $355.00 target price on shares of Veeva Systems in a report on Friday, November 21st. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Veeva Systems in a research report on Monday. Wells Fargo & Company cut their target price on Veeva Systems from $341.00 to $333.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 25th. BMO Capital Markets initiated coverage on Veeva Systems in a research note on Thursday, November 13th. They set a “market perform” rating and a $300.00 target price for the company. Finally, TD Cowen raised Veeva Systems from a “hold” rating to a “buy” rating and upped their price target for the company from $297.00 to $380.00 in a report on Tuesday, October 7th. Eighteen equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, Veeva Systems has a consensus rating of “Moderate Buy” and a consensus price target of $307.42.

Veeva Systems Company Profile

Veeva Systems (NYSE: VEEV) is a cloud software company that develops industry-specific applications and data solutions for the global life sciences sector. Founded in 2007 and headquartered in Pleasanton, California, Veeva focuses on helping pharmaceutical, biotechnology, medical device and consumer health companies manage regulated content, clinical and regulatory processes, quality systems, and commercial operations in a compliant, cloud-native environment. The company completed its initial public offering in 2013 and has since expanded its product suite and international footprint.

Veeva’s product portfolio centers on its Vault platform and related application suites, which provide content and data management, clinical trial and regulatory workflows, quality management, and structured commercial capabilities such as customer relationship management and promotional content management.